Arthur R. McGivern

Arthur R. McGivern

Arthur R. McGivern

Arthur McGivern is a partner in Goodwin Procter’s Technology & Life Sciences Group and a member of its Life Sciences and Capital Markets Practices. Mr. McGivern works on a wide variety of public and private securities offerings, mergers and acquisitions and other complex transactions in the life sciences sector. He also represents public and private companies in their ongoing corporate matters, including SEC compliance and corporate governance, as well as investment banks, hedge funds and other private investment funds in public securities-related matters.

Professional Experience

Prior to joining Goodwin, Mr. McGivern was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.


Mr. McGivern is recognized in the 2013 edition of The Legal 500 United States for his work in Healthcare: Life Sciences.

Areas of Practice


Mr. McGivern’s recent representations include:

  • Intellia Therapeutics in its (i) $15 million Series A financing, (ii) foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology, (iii) exclusive collaboration and license agreement with Novartis, (iv) exclusive collaboration and license agreement with Regeneron and (v) $112 million initial public offering and concurrent $55 million private placements
  • Repligen Corporation, a NASDAQ-listed bioprocessing company, in a $115 million convertible note offering and in its acquisitions of (i) Novozymes Biopharma’s bioprocessing business, (ii) Refine Technology’s Alternating Tangential Flow (“ATF”) System, and (iii) Atoll GmbH
  • Royalty Pharma in its purchases of royalties in transactions valued at more than $7 billion, including (i) its $3.3 billion acquisition of the Cystic Fibrosis Foundation’s royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments, the largest pharmaceutical royalty purchase ever completed, (ii) its $1.14 billion acquisition of UCLA’s royalties on Xtandi and (iii) a synthetic royalty financing with Sanofi
  • Foundation Medicine, a cancer diagnostics company, in (i) a $55 million private financing, (ii) its subsequent $120 million initial public offering on the NASDAQ Stock Market and (iii) its collaboration agreement and equity transaction with Roche, total value in excess of $1 billion
  • Esperion Therapeutics, a Michigan-based pharmaceutical company developing a treatment for elevated levels of LDL cholesterol, in (i) a $17 million private financing, (ii) its subsequent $80 million initial public offering on the NASDAQ Stock Market and (iii) two follow-on public offerings, raising over $272 million
  • Nimbus Therapeutics in its (i) co-development collaboration with Shire plc which focused on of first-in-class small molecule treatments for several rare genetic diseases, (ii) co-development collaboration with Monsanto which focused on a broad-spectrum fungicides, (iii) private financings, including a $24 million Series A financing and $43 million Series B financing and (iv) sale of its Acetyl-CoA Carboxylase (ACC) inhibitor program to Gilead for $400 million upfront and the potential to receive an additional $800 million
  • Alnylam Pharmaceuticals in its transformational alliance for the development and commercialization of RNAi therapeutics with Genzyme, a Sanofi company, under which Genzyme purchased $700 million of Alnylam common equity and obtained a series of options to purchase regional (i.e., ex-North America and Western Europe), co-development or global licenses to various Alnylam product candidates
  • Warp Drive Bio, a strategic partnership between Third Rock Ventures and Sanofi, in Warp Drive Bio’s initial $125 million financing and defined collaboration deal and the 2016 extension of this collaboration
  • Agenus Inc. in a $115 million royalty bond financing transaction with an investor group led by Oberland Capital
  • SmartCells, Inc., a private biotechnology company developing a glucose responsive insulin, in its capital raising and ongoing operations as well as its ultimate sale to Merck & Co. for an upfront cash payment as well as potential clinical development and regulatory milestones in excess of $500 million and royalties
  • Yumanity Therapeutics in its $45 million Series A financing
  • Underwriters and selling stockholders in initial public and following equity offerings raising more than $1 billion
  • Intellect Medical, a private medical device company developing technologies for deep brain stimulation, in its sale to Boston Scientific in a transaction valued at $78 million



J.D., 2004
Boston University School of Law

(cum laude)

B.S.C.E., 1997
Tufts University

(cum laude)



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers